PRECISION BIOSCIENCES INC
DTIL evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $169.5M
- Lead Asset:
- fosfomycin (Approved)
What it means
What to watch
Prepared research question
What matters most for DTIL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DTIL
Precision BioSciences Inc (DTIL) is a clinical-stage gene editing company leveraging its proprietary ARCUS® platform to develop in vivo therapies for high-unmet-need diseases, with lead programs in chronic hepatitis B (PBGENE-HBV) and Duchenne muscular dystrophy (PBGENE-DMD).
Key risk: No revenue, ongoing losses
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 16 clinical trials · 6 FDA decisions for PRECISION BIOSCIENCES INC.
Precision BioSciences Inc (DTIL) is a clinical-stage gene editing company leveraging its proprietary ARCUS® platform to develop in vivo therapies for high-unmet-need diseases, with lead programs in chronic hepatitis B (PBGENE-HBV) and Duchenne muscular dystrophy (PBGENE-DMD).
- Cash & equivalents of $86.1M as of 2026-06-30 [sec].
- Total revenue of $0.0M and net income of -$32.7M for the period ended 2026-06-30 [sec].
- Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts with data updates expected at medical conferences in 2026 [news · 2026-01-12].
- PBGENE-DMD expecting IND clearance in Q1 2026 for Phase 1/2 FUNCTION-DMD study [news · 2026-01-12].
- Clinical trial application approved to expand ELIMINATE-B trial into France and Romania [news · 2026-04-15].
What works
- Strong cash position of $86.1M as of 2026-06-30 provides runway for ongoing clinical programs [sec].
- Lead program PBGENE-HBV is advancing in a global Phase 1/2a trial with expansion into European countries, broadening patient enrollment [news · 2026-04-15].
- PBGENE-DMD program has generated preclinical data presented at ASGCT 2026, supporting its advancement toward the clinic [news · 2026-05-14].
- Recent promotions of Alex Kelly to COO and Naresh Tanna to CFO effective August 1, 2026, indicate leadership stability as programs advance [news · 2026-07-27].
What to weigh
- No revenue reported as of 2026-06-30, reflecting the pre-commercial stage of all programs [sec].
- Net loss of $32.7M for the period ended 2026-06-30 highlights ongoing operating expenses without product revenue [sec].
- Shareholders' equity of $45.3M as of 2026-06-30 is less than half of cash, suggesting significant accumulated deficit or liabilities [sec].
- Both lead programs (PBGENE-HBV and PBGENE-DMD) are in early clinical or pre-clinical stages, with no approved products or guaranteed regulatory outcomes [news · 2026-01-12].
From the filings
Quoted directly from source documents.
Phase 1/2a ELIMINATE-B trial ongoing
“Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts”
News · January 12, 2026
Expansion of ELIMINATE-B trial into France and Romania
“France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patient enrollment”
News · April 15, 2026
Leadership promotions effective August 1, 2026
“Precision BioSciences Promotes Alex Kelly To COO And Naresh Tanna To CFO, Effective August 1, 2026”
News · July 27, 2026
Risks & what to watch (3)›
Key risks
- No revenue, ongoing losses — Zero revenue and $32.7M net loss as of 2026-06-30; company relies entirely on cash reserves [sec].
- Early-stage pipeline
- Cash runway uncertainty — Cash dropped from ~$137M (Dec 2025 est.) to $86.1M (Jun 2026); burn rate may shorten runway [sec].
What to watch
- Clinical data updates for PBGENE-HBV from the ELIMINATE-B trial expected at medical conferences in 2026 [news · 2026-01-12].
- IND clearance and start of Phase 1/2 FUNCTION-DMD study for PBGENE-DMD, anticipated in Q1 2026 [news · 2026-01-12].
- Investor webcast on late-breaking PBGENE-HBV data announced for May 2026 [news · 2026-05-21].
- Cash burn rate and any new financing or partnership announcements given the declining cash position [sec].
Sources: Catalysts · Competitor trials · News · Generated October 11, 2026 · How we verify sources →
Run PRECISION BIOSCIENCES INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PRECISION BIOSCIENCES INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.78 · 0% dilution
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 4.7%
- Days to cover
- 3.1
- Shares short
- 1,171,027
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DTIL short interestGovernance
Frequently asked questions
What is the AI investment thesis for PRECISION BIOSCIENCES INC?
Precision BioSciences Inc (DTIL) is a clinical-stage gene editing company leveraging its proprietary ARCUS® platform to develop in vivo therapies for high-unmet-need diseases, with lead programs in chronic hepatitis B (PBGENE-HBV) and Duchenne muscular dystrophy (PBGENE-DMD).
What is PRECISION BIOSCIENCES INC's lead drug candidate?
PRECISION BIOSCIENCES INC's most advanced tracked candidate is fosfomycin (Approved).
Who is the CEO of PRECISION BIOSCIENCES INC?
Mr. Michael Amoroso is the chief executive officer of PRECISION BIOSCIENCES INC (DTIL).
Where is PRECISION BIOSCIENCES INC headquartered?
PRECISION BIOSCIENCES INC (DTIL) is headquartered in Durham, NC, United States.
What therapeutic areas does PRECISION BIOSCIENCES INC focus on?
PRECISION BIOSCIENCES INC develops therapies across Oncology, Rare Disease, Gene Therapy, Infectious Disease, Dermatology, Nephrology, Musculoskeletal, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.